Therapy for medullary thyroid cancer

Thyroid Cancer (Second Edition)

Volumn , Issue , 2005, Pages 335-345

  Gimm, O ^a   Dralle, H ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952502297     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-27845-1_19     Document Type: Chapter

References (45)

1. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Frank M, Schmidberger H, Raue F, Becker W (1997) Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57:5309-5319
2. Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132-138
3. Chi DD, Moley JF (1998) Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin North Am 7:681-706
4. Christensen SB, Ljungberg O, Tibblin S (1984) A clinical epidemiologic study of thyroid carcinoma in Malmo, Sweden. Curr Probl Cancer 8:1-49
5. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML (1996) Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 20:814-820; discussion 820-811
6. Dilla T, Velasco JA, Medina DL, Gonzalez-Palacios JF, Santisteban P (2000) The MDM 2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells. Endocrinology 141:420-429
7. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathological variables. Cancer 77:1556-1565
8. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24:112-121
9. Dralle H, Gimm O (1996) Lymph node excision in thyroid carcinoma. Chirurg 67:788-806
10. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Hoppner W (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744-750; discussion 750-741
11. Dralle H, Scheumann GF, Kotzerke J, Brabant EG (1992) Surgical management of MEN 2. Rec Res Cancer Res 125:167-195
12. Dralle H, Scheumann GF, Proye C, Bacourt F, Frilling A, Limbert F, Gheri G, Henry JF, Berner M, Niederle B et al (1995) The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med 238:357-361
13. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BA, Mulligan LM (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579
14. Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, Evans DB (1999) Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230:697-707
15. Frank-Raue K, Ziegler R, Raue F (1993) The use of octreotide in the treatment of medullary thyroid carcinoma. Horm Metab Res [Suppl] 27:44-47
16. Freyer G, Dazord A, Schlumberger M, Conte-Devolx B, Lig neau B, Tril let-Lenoir V, Lenoir GM (1999) Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation. Ann Oncol 10:87-95
17. Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 122:1124-1130; discussion 1130-1121
18. Gimm O, Dralle H (1999) C-cell cancer-prevention and treatment. Langenbecks Arch Surg 384:16-23
19. Gimm O, Ukkat J, Dralle H (1998) Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562-567; discussion 567-568
20. Hazard JB, Hawk WA, Crile G (1959) Medullary (solid) carcinoma of the thyroid-a clini-copathological entity. J Clin Endocrinol Metab 19:152-161
21. Hoie J, Jorgensen OG, Stenwig AE, Langmark F (1988) Medullary thyroid cancer in Norway. A 30-year experience. Acta Chir Scand 154:339-343
22. Horn RC (1951) Carcinoma of the thyroid: description of a distinctive morphological variant and report of seven cases. Cancer 4:697-707
23. Jaquet AJ (1906) Ein Fall von metastasierenden Amyloidtumoren (Lymphosarcoma). Virchows Archiv (Pathol Anat) 185:251
24. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM (1996) Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 37:905-911
25. Kebebew E, Tresler PA, Siperstein AE, Duh QY, Clark OH (1999) Normal thyroid pathology in patients undergoing thyroidectomy for finding a RET gene germline mutation: a report of three cases and review of the literature. Thyroid 9:127-131
26. Machens A, Behrmann C, Dralle H (2000) Chemoembolization of liver metastases from medullary thyroid carcinoma. Ann Intern Med 132:596-597
27. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H (2001) Genotype-phe-notype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109
28. Mahler C, Verhelst J, de Longueville M, Harris A (1990) Long-term treatment of meta-static medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33:261-269
29. Marzano LA, Porcelli A, Biondi B, Lupoli G, Delrio P, Lombardi G, Zarrilli L (1995) Surgical management and follow-up of medullary thyroid carcinoma. J Surg Oncol 59:162-168
30. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K (2002) Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26:1023-1028
31. Moley JF (1995) Medullary thyroid cancer. Surg Clin North Am 75:405-420
32. Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880-887; discussion 887-888
33. Moley JF, Dilley WG, DeBenedetti MK (1997) Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225:734-740; discussion 740-733
34. Moley JF, Wells SA, Dilley WG, Tisell LE (1993) Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 114:1090-1095; discussion 1095-1096
35. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC, Bstandig B, Modigliani E, Morange S, Schlumberger M, Conte-Devolx B (1999) Early or prophylactic thyroid-ectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. Eur J Endocrinol 141:468-474
36. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A (1994) Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma (see Com ments). J Clin Endocrinol Metab 78:826-829
37. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P, Easton DF (1988) Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1:397-401
38. Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H, Hofer R, Ritter M, Seif F, Buhr H et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 71:7-12
39. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL, Fombeur JP (1995) Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules (see Comments). Clin Endocrinol (Oxf) 42:453-460
40. Stein R, Chen S, Reed L, Richel H, Goldenberg DM (2002) Combining radioimmuno-therapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 94:51-61
41. Van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395-400; discussion 400-401
42. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B (1997) Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 82:1589-1593
43. Wells SA Jr, Baylin SB, Gann DS, Farrell RE, Dilley WG, Preissig SH, Linehan WM, Cooper CW (1978) Medullary thyroid carcinoma: relationship of method of diagnosis to pathological staging. Ann Surg 188:377-383
44. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, De-Benedetti MK, Dilley WG, Moley JF et al (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-247; discussion 247-250
45. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB (2003) Multiple endocrine neoplasia type 2: evaluation of the genotype-pheno-type relationship. Arch Surg 138:409-416; discussion 416